Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May 13;20(1):29.
doi: 10.1186/s12981-023-00520-4.

Dual trajectories of antiretroviral therapy adherence and polypharmacy in women with HIV in the United States

Abubaker Ibrahim Elbur  1 , Musie Ghebremichael  2 , Deborah Konkle-Parker  3 , Deborah L Jones  4 , Shelby Collins  5 , Adaora A Adimora  6 , Michael F Schneider  7 , Mardge H Cohen  8 , Bani Tamraz  9 , Michael Plankey  10 , Tracey Wilson  11 , Adebola Adedimeji  12 , Jessica E Haberer  13 , Denise L Jacobson  14
Affiliations

Dual trajectories of antiretroviral therapy adherence and polypharmacy in women with HIV in the United States

Abubaker Ibrahim Elbur et al. AIDS Res Ther. .

Abstract

Background: Polypharmacy, using five or more medications, may increase the risk of nonadherence to prescribed treatment. We aimed to identify the interrelationship between trajectories of adherence to antiretroviral therapy (ART) and polypharmacy.

Methods: We included women with HIV (aged ≥ 18) enrolled in the Women's Interagency HIV Study in the United States from 2014 to 2019. We used group-based trajectory modeling (GBTM) to identify trajectories of adherence to ART and polypharmacy and the dual GBTM to identify the interrelationship between adherence and polypharmacy.

Results: Overall, 1,538 were eligible (median age of 49 years). GBTM analysis revealed five latent trajectories of adherence with 42% of women grouped in the consistently moderate trajectory. GBTM identified four polypharmacy trajectories with 45% categorized in the consistently low group.

Conclusions: The joint model did not reveal any interrelationship between ART adherence and polypharmacy trajectories. Future research should consider examining the interrelationship between both variables using objective measures of adherence.

PubMed Disclaimer

Conflict of interest statement

No relevant financial or non-financial competing interests to report.

Figures

Fig. 1
Fig. 1
a Trends of > 95% self-report adherence to ART over the study period. b Trends of polypharmacy (5 + medications) over the study period
Fig. 2
Fig. 2
Trajectories of adherence to antiretroviral therapy
Fig. 3
Fig. 3
Trajectories of polypharmacy (considering all medications)
See this image and copyright information in PMC

References

    1. Centers for Disease Control and Prevention, Surveillance Report HIV. 2020; vol. 33. http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html. Published May 2022. Accessed October, 17, 2022.
    1. Benning L, Mantsios A, Kerrigan D, et al. Examining adherence barriers among women with HIV to tailor outreach for long-acting injectable antiretroviral therapy. BMC Womens Health. 2020;20:152. doi: 10.1186/s12905-020-01011-8. - DOI - PMC - PubMed
    1. Menéndez-Arias L, Delgado R. Update and latest advances in antiretroviral therapy. Trends Pharmacol Sci. 2022;43:16–29. doi: 10.1016/j.tips.2021.10.004. - DOI - PubMed
    1. Collins LF, Sheth AN, Mehta CC, et al. The prevalence and burden of non-AIDS comorbidities among women living with or at risk for human immunodeficiency virus infection in the United States. Clin Infect Dis. 2021;72:1301–11. doi: 10.1093/cid/ciaa204. - DOI - PMC - PubMed
    1. Edelman EJ, Gordon KS, Glover J, et al. The next therapeutic challenge in HIV: polypharmacy. Drugs Aging. 2013;30:613–28. doi: 10.1007/s40266-013-0093-9. - DOI - PMC - PubMed

Publication types

Substances